Aquestive Therapeutics received FDA acceptance for its Anaphylm New Drug Application resubmission, aiming for a March 16, 2027 PDUFA date. The resubmission addresses previous FDA concerns by providing improved human factors data that significantly reduces packaging and administration errors. The company is expected to generate over $250 million in annual revenue by 2030 if approved, despite facing competition and reimbursement risks. Additional pipeline products like Libervant and AQST-108 offer further growth potential, with Libervant projected to contribute around $50 million annually after 2027 exclusivity ends.
Aquestive's FDA acceptance news is context for health-sector trading activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 16, 2026 23:21 WIB: out of 150 priced US health-sector stocks, 36 rose and 114 fell. Notable movers include IOVA at USD 13.69 with a 7.00% drop, WGS at USD 65.48 down 6.75% but with 96% buy orders, and HRTX at USD 0.35 down 6.64% with 60% sell orders.
Quaker Chemical Corporation's stock recently dipped about 2.81% over the last 10 days after gaining 0.49% in the past month, potentially offering a lower entry point for investors. Analysts project a 17.24% price growth potential with a target price ...
Citigroup has raised its price target for Travelers to $395 following the company's strong third-quarter 2026 results, where core earnings per share reached $9.18, significantly surpassing analyst expectations. Travelers also improved its combined ra...
F.N.B. Corporation will report its Q3 2026 earnings on October 19, with analysts forecasting earnings of $0.43 per share, a 4.9% increase from last year. Revenue is expected to rise about 4% to around $476 million. Investors will focus on management'...
Nvidia's market value dropped by $200 billion following OpenAI's revenue run rate announcement, which came in $18 billion below expectations. This significant shortfall has sparked concerns among investors about the growth prospects of AI-related com...
Kuaishou Technology has officially launched Kling 4.0, its next-generation AI video generation model, focusing on improved stability in dynamic scenes, longer continuous video generation up to 30 seconds, and enhanced creative control with support fo...
